The PD-L1–directed antibody-drug conjugate (ADC) HLX43 has received orphan drug designation from the FDA for the treatment of patients with thymic epithelial tumors.1
At a data cutoff of June 28, 2025, findings from a phase 1 study…
The PD-L1–directed antibody-drug conjugate (ADC) HLX43 has received orphan drug designation from the FDA for the treatment of patients with thymic epithelial tumors.1
At a data cutoff of June 28, 2025, findings from a phase 1 study…